Second generation antipsychotics (SGAs) are effective options in the treatment of schizophrenia and mood disorders, each with characteristic efficacy and safety features. In order to optimize the balance between efficacy and side effects, it is of upmost importance to match compound specificity against patient clinical profile. As the number of SGAs increased, this review can assist physicians in the prescription of three novel SGAs already on the market, namely lurasidone, brexpiprazole, cariprazine, and lumateperone, which is in the approval phase for schizophrenia treatment at the FDA. Besides schizophrenia, EMA and/or FDA approved lurasidone for bipolar depression, brexpiprazole as augmentation in major depressive disorder and cariprazine for the acute treatment of manic or mixed episodes associated with bipolar I disorder. These new antipsychotics were developed with the aim of improving efficacy on negative and depressive symptoms and reducing metabolic and cardiovascular side effects compared to prior SGAs, while keeping the risk of extrapyramidal symptoms low. They succeeded quite well in containing these side effects, despite weight gain during acute treatment remains a possible concern for brexpiprazole, while cariprazine and lurasidone show higher risk of akathisia compared to placebo and other SGAs such as olanzapine. The available studies support the expected benefits on negative symptoms, cognitive dysfunction and depressive symptoms, while the overall effect on acute psychotic symptoms may be similar to other SGAs such as quetiapine, aripiprazole and ziprasidone. The discussed new antipsychotics represent useful therapeutic options but their efficacy and side effect profiles should be considered to personalize prescription.
Keywords: Antipsychotics; Brexpiprazole; Cariprazine; Lumateperone; Lurasidone; Personalized medicine.
Copyright © 2019 Elsevier B.V. and ECNP. All rights reserved.
Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.CNS Drugs. 2019 Jun;33(6):549-566. doi: 10.1007/s40263-019-00625-3. CNS Drugs. 2019. PMID: 31065941 Review.
Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. doi: 10.18553/jmcp.2012.18.s5-b.1. J Manag Care Pharm. 2012. PMID: 22784311 Review.
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. CNS Drugs. 2012. PMID: 22900950 Review.
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Ther Clin Risk Manag. 2017 Jun 29;13:757-777. doi: 10.2147/TCRM.S117321. eCollection 2017. Ther Clin Risk Manag. 2017. PMID: 28721057 Free PMC article. Review.
Cited by 2 articles
Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes.J Biomol Struct Dyn. 2020 Apr 26:1-13. doi: 10.1080/07391102.2020.1758791. Online ahead of print. J Biomol Struct Dyn. 2020. PMID: 32306862 Free PMC article.
Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data.Ther Adv Psychopharmacol. 2020 Feb 12;10:2045125320905752. doi: 10.1177/2045125320905752. eCollection 2020. Ther Adv Psychopharmacol. 2020. PMID: 32110377 Free PMC article. Review.